Continuous intravesical instillation of epirubicin immediately after transurethral resection of superficial bladder cancer: A prospective controlled study

Shinya Maekawa, Hiroshi Suzuki, Kazutoshi Ohkubo, Yoshitaka Aoki, Takashi Okada, Hiroshi Maeda, Keiji Ogura, Yoichi Arai

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Abstract

Between November 1994 and July 1996, 45 patients with superficial bladder tumor were assigned to two groups before transurethral resection of bladder tumor. Twenty-one of the 45 patients were instilled with 20 mg epirubicin before endoscopic resection then continuously irrigated with 40 μg/ml epirubicin solution for 20 hours immediately after surgery; 24 of the 45 patients received continuous irrigation with saline in the same manner. The patients were assessed by cystoscopy and urinary cytology every 3 months during the first 2 years and every 6 months thereafter. One year recurrencefree rates in the treated and control groups were 56% and 32%, respectively. The recurrence-free period tended to be longer in the treated group than in the control group, although the difference was not significant (p=0.17). One year recurrence-free rates in the treated and control groups for the patients with solitary tumor were 88% and 48%, respectively, the difference being marginally significant (p=0.06). These results suggested that continuous bladder irrigation with epirubicin was effective for patients with a single tumor. Therefore, the long-term prophylactic therapy for a single tumor was an overtreatment. Prophylactic intravesical chemotherapy for superficial bladder cancer was proposed to be stratified by the number of tumors, single or multiple.

Original languageEnglish
Pages (from-to)301-306
Number of pages6
JournalActa Urologica Japonica
Volume46
Issue number5
Publication statusPublished - 2000 May 1

Keywords

  • Bladder cancer
  • Continuous intravesical instillation
  • Epirubicin

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Continuous intravesical instillation of epirubicin immediately after transurethral resection of superficial bladder cancer: A prospective controlled study'. Together they form a unique fingerprint.

Cite this